CDK4 and breast cancer: Indeed, several potential biomarkers have been identified using breast cancer cell models resistant to the single-agent CDK4/6i, and not to the clinically-used combination of CDK4/6i and ET, and thus do not likely reflect the possible multi-step process of resistance wherein cells undergo early adaptation before long term resistance [12].